# Johnson & Johnson (JNJ)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/johnson-and-johnson/ JSON: https://steadybase.io/company/johnson-and-johnson.json Checked Nov 10, 2026. Latest filing read: Oct 21, 2026.

## Company

- Legal name: JOHNSON & JOHNSON
- Ticker: JNJ (NYSE)
- SEC CIK: 0000200406
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: New Brunswick, NJ
- Fiscal year ends: January 3
- SEC filer category: Large accelerated filer
- Website: jnj.com
- Investor relations: https://www.investor.jnj.com/overview/default.aspx
- LinkedIn: https://www.linkedin.com/company/johnson-&-johnson
- Next earnings date: Jan 13, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $94.2B for the fiscal year ended Dec 28, 2025 (10-K filed Feb 11, 2026). Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000016/0000200406-26-000016-index.html
- Net income: $26.8B for the fiscal year ended Dec 28, 2025 (10-K filed Feb 11, 2026). Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000016/0000200406-26-000016-index.html
- SG&A: $23.7B for the fiscal year ended Dec 28, 2025 (10-K filed Feb 11, 2026). Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000016/0000200406-26-000016-index.html
- Employees: 138,200 as of Feb 11, 2026, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000016/0000200406-26-000016-index.html
- Shares outstanding: 2,407,310,266 as of Oct 15, 2026 (10-Q filed Oct 21, 2026). Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000197/0000200406-26-000197-index.html
- Auditor: Pricewaterhousecoopers LLP, Florham Park, New Jersey, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000016/jnj-20251228.htm

## Business

Johnson & Johnson and its subsidiaries (the Company) have approximately 138,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Johnson & Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company’s primary focus is products related to human health and well-being. Johnson & Johnson was incorporated in the State of New Jersey in 1887.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/200406/000020040626000016/jnj-20251228.htm

## Annual results

| Fiscal year ended | Revenue | Net income | SG&A |
|---|---|---|---|
| Dec 28, 2025 | $94.2B | $26.8B | $23.7B |
| Dec 29, 2024 | $88.8B | $14.1B | $22.9B |
| Dec 31, 2023 | $85.2B | $35.2B | $21.5B |
| Jan 1, 2023 | $80.0B | $17.9B | $20.2B |
| Jan 2, 2022 | $78.7B | $20.9B | $20.1B |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/johnson-and-johnson.json

## Officers and directors

- Joaquin Duato, CEO and Chairman of the Board. LinkedIn: https://linkedin.com/in/joaquinduato. Source: Form 4 filed Aug 14, 2026, https://www.sec.gov/Archives/edgar/data/200406/000020040626000173/0000200406-26-000173-index.htm
- Joseph J. Wolk, Exec VP, CFO. Source: Form 4 filed Feb 18, 2026, https://www.sec.gov/Archives/edgar/data/200406/000020040626000041/0000200406-26-000041-index.htm
- Timothy Schmid, EVP, WW Chair, MedTech. Source: Form 4 filed Sep 4, 2026, https://www.sec.gov/Archives/edgar/data/200406/000020040626000179/0000200406-26-000179-index.htm
- Thomas Cavanaugh, EVP WW Chair, Innovative Med.. Source: Form 3 filed Sep 1, 2026, https://www.sec.gov/Archives/edgar/data/200406/000020040626000177/0000200406-26-000177-index.htm
- Jennifer L. Taubert, EVP, WWC. Innovative Medicine. Source: Form 4 filed Aug 18, 2026, https://www.sec.gov/Archives/edgar/data/200406/000020040626000175/0000200406-26-000175-index.htm
- Elizabeth Forminard, EVP, Chief Legal Officer. LinkedIn: https://linkedin.com/in/elizabeth-forminard-a19774a6. Source: Form 4 filed Aug 7, 2026, https://www.sec.gov/Archives/edgar/data/200406/000020040626000169/0000200406-26-000169-index.htm
- Vanessa Broadhurst, EVP, Global Corp Affairs. LinkedIn: https://linkedin.com/in/vanessabroadhurst. Source: Form 4 filed Jul 21, 2026, https://www.sec.gov/Archives/edgar/data/200406/000020040626000148/0000200406-26-000148-index.htm
- Kathryn E. Wengel, EVP, Chief TO and Risk Officer. LinkedIn: https://linkedin.com/in/kathryn-wengel. Source: Form 4 filed Jun 12, 2026, https://www.sec.gov/Archives/edgar/data/200406/000020040626000127/0000200406-26-000127-index.htm
- John C. Reed, EVP, Innovative Medicine, R&D. Source: Form 4 filed May 4, 2026, https://www.sec.gov/Archives/edgar/data/200406/000020040626000115/0000200406-26-000115-index.htm
- Robert J. Decker, VP Corporate Controller. Source: Form 4 filed Mar 3, 2026, https://www.sec.gov/Archives/edgar/data/200406/000020040626000048/0000200406-26-000048-index.htm
- James D. Swanson, EVP, CIO. Source: Form 4 filed Feb 18, 2026, https://www.sec.gov/Archives/edgar/data/200406/000020040626000044/0000200406-26-000044-index.htm
- Kristen Mulholland, EVP, Chief HR Officer. Source: Form 4 filed Feb 18, 2026, https://www.sec.gov/Archives/edgar/data/200406/000020040626000042/0000200406-26-000042-index.htm
- R. J. Decker Jr., Controller and Chief Accounting Officer (Principal Accounting Officer). Source: 10-K filed Feb 11, 2026, https://www.sec.gov/Archives/edgar/data/200406/000020040626000016/jnj-20251228.htm
- Jennifer A. Doudna, Board member (per proxy). Source: DEF 14A filed Mar 11, 2026, https://www.sec.gov/Archives/edgar/data/200406/000020040626000063/jnj-20260309.htm
- Marillyn Hewson, Board member (per proxy). Source: DEF 14A filed Mar 11, 2026, https://www.sec.gov/Archives/edgar/data/200406/000020040626000063/jnj-20260309.htm

## Recent 8-K events

- Oct 13, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000189/jnj-20261013.htm
- Aug 4, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000167/jnj-20260804.htm
- Jul 29, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000163/jnj-20260729.htm
- Jul 28, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000155/jnj-20260727.htm
- Jul 15, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000146/jnj-20260715.htm
- Apr 28, 2026: Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000089/jnj-20260423.htm
- Apr 14, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000076/jnj-20260414.htm
- Jan 21, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000002/jnj-20260121.htm
- Oct 14, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040625000201/jnj-20251014.htm
- Sep 9, 2025: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040625000190/jnj-20250908.htm

## Insider trades (Form 4)

- Sep 2, 2026: Timothy Schmid (EVP, WW Chair, MedTech) sold 33,597 shares, about $9.2M. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000179/0000200406-26-000179-index.htm
- Aug 17, 2026: Jennifer L. Taubert (EVP, WWC. Innovative Medicine) sold 15,000 shares, about $4.0M. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000175/0000200406-26-000175-index.htm
- Aug 13, 2026: Joaquin Duato (CEO and Chairman of the Board) sold 123,291 shares, about $32.2M. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000173/0000200406-26-000173-index.htm
- Aug 6, 2026: Elizabeth Forminard (EVP, Chief Legal Officer) sold 15,918 shares, about $4.1M. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000169/0000200406-26-000169-index.htm
- Aug 5, 2026: Joaquin Duato (CEO and Chairman of the Board) sold 48,480 shares, about $12.5M. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000171/0000200406-26-000171-index.htm
- Jul 20, 2026: Vanessa Broadhurst (EVP, Global Corp Affairs) sold 23,054 shares, about $5.8M. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000148/0000200406-26-000148-index.htm
- Jun 11, 2026: Kathryn E. Wengel (EVP, Chief TO and Risk Officer) sold 10,000 shares, about $2.4M. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000127/0000200406-26-000127-index.htm
- Feb 27, 2026: Robert J. Decker (VP Corporate Controller) sold 4,075 shares, about $1.0M. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000048/0000200406-26-000048-index.htm
- Feb 20, 2026: Timothy Schmid (EVP, WW Chair, MedTech) sold 1,322 shares, about $324,763. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000046/0000200406-26-000046-index.htm
- Feb 18, 2026: Timothy Schmid (EVP, WW Chair, MedTech) sold 22,623 shares, about $5.5M. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000036/0000200406-26-000036-index.htm
- Feb 17, 2026: James D. Swanson (EVP, CIO) sold 62,080 shares, about $15.1M. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000044/0000200406-26-000044-index.htm
- Feb 17, 2026: Joseph J. Wolk (Exec VP, CFO) sold 89,654 shares, about $21.8M. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000041/0000200406-26-000041-index.htm
- Feb 17, 2026: John C. Reed (EVP, Innovative Medicine, R&D) sold 53,931 shares, about $13.1M. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000039/0000200406-26-000039-index.htm
- Feb 17, 2026: Vanessa Broadhurst (EVP, Global Corp Affairs) sold 6,197 shares, about $1.5M. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000034/0000200406-26-000034-index.htm
- Jan 26, 2026: Joaquin Duato (CEO and Chairman of the Board) sold 100,000 shares, about $22.1M. Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000004/0000200406-26-000004-index.htm

## What management said

- "Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio" Joaquin Duato, Chairman and Chief Executive Officer (8-K filed Oct 13, 2026). Source: https://www.sec.gov/Archives/edgar/data/200406/000020040626000189/a2026q3exhibit991.htm

## Latest filings

- 8-K filed Oct 13, 2026: https://www.sec.gov/Archives/edgar/data/200406/000020040626000189/jnj-20261013.htm
- 10-K filed Feb 11, 2026: https://www.sec.gov/Archives/edgar/data/200406/000020040626000016/jnj-20251228.htm
- 10-Q filed Oct 21, 2026: https://www.sec.gov/Archives/edgar/data/200406/000020040626000197/jnj-20260927.htm
- DEF 14A filed Mar 11, 2026: https://www.sec.gov/Archives/edgar/data/200406/000020040626000063/jnj-20260309.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/